FDA Drug Safety Communication: Initial safety trial results find Tofacitinib, used for arthritis and ulcerative colitis, may increase the risk of serious heart-related problems and cancer

Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication – Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine – U.S. Food & Drug Administration

Commentary: Arthritis, Colitis Drug Tied to Heart-Related Problems and Cancer – NEJM Journal Watch